[Effectiveness and the methods of using streptokinase in myocardial infarct and preinfarct stenocardia].
The effectiveness of streptokinase treatment of patients with myocardial infarction as compared to the control group and patients given anticoagulants is analysed. It is shown that the frequency of recurrent myocardial infarctions, congestive circulatory insufficiency, shock, and thromboembolic complications is lower in the group of patients treated with streptokinase than in the control group. Streptokinase improves the course of the disease and the prognosis in patients with preinfarction angina pectoris. The effect of streptokinase is higher in the first 3--6 hours after the development of myocardial infarction and in individuals under the age of 65. The effectiveness of the treatment does not diminish when the drug is injected for a short time and in small doses (300,000--750,000 U).
D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use; D004341:Drug Evaluation; D004562:Electrocardiography; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*; D012770:Shock, Cardiogenic / Q000188:drug therapy; D013300:Streptokinase / Q000008:administration & dosage*; D013997:Time Factors
D000925:Anticoagulants; D013300:Streptokinase
Effektivnost' i metodika primeneniia streptokinazy u bol'nykh infarktom miokarda i predynfarktnoi stenokardieĭ.